- Clone:
- REA393 | 194128
- Type of antibody:
- Primary antibodies, Recombinant antibodies
- Isotype:
- recombinant human IgG1
- Applications:
- FC, MICS, IF, IHC Glossary
- Select a conjugate:
- Select a size:
Related products for Siglec-5/Siglec-14 Antibody, anti-human, REAfinity™
Clone REA393 recognizes the human siglec-5 and siglec-14 antigens, which are both single pass transmembrane protein members of the immunoglobulin superfamily. Siglec-5 is also known as CD170. Siglec-5 has four extracellular Ig-like domains and a cytosolic inhibitory motif. Siglec-14 was discovered with three Ig-like domains and has almost complete sequence identity with siglec-5 at the first two Ig-like domains, shows a glycan binding preference similar to that of siglec-5, and associates with the activating adapter protein DAP12. Siglec-5 is expressed on granulocytes and monocytes as well as on plasmacytoid dendritic cells, monocyte-derived dendritic cells, and macrophages. It is potentially involved in the negative regulation of innate immune responses, and also suggested to be a useful diagnostic and therapeutic marker for acute myelogenous leukemia. Siglec-14 is expressed on granulocytes and B cells. Some individuals lack the expression of siglec-14, while they all express siglec-5.
Additional information: Clone REA393 displays negligible binding to Fc receptors.
CD170, CD33L2, OB-BP2, OBBP2, SIGLEC5, Siglec14
Technical specifications
Recombinant antibodies at Miltenyi Biotec
As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.
The Miltenyi way of generating best-in-class antibodies and antibody conjugates
At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.
Infusing our unique expertise
Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.
Maximizing value for your research
By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:
reduce undesirable binding to Fc gamma receptors,
- eliminate destabilizing amino acid motifs,
- increase specific bonding affinity for stronger, more accurate targeting, and
- optimize fluorochrome conjugation for brighter and clearer signals.
In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.
Better science with quality antibodies
Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).
To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.
Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.
You have previously chosen International as your location.
What do you want to do?